Group items matching

in title, tags, annotations or url

This Research Fund is opening a call for projects in the following areas: * Protecting vulnerable populations from epidemics and catastrophes, including COVID-19: be it migrants, informal settlements, workers in the informal economy, isolated people, people with disabilities, the elderly * Improving data collection and quality in health: how can data and technology help us get out of the crisis, understand it and mitigate it? How can it inform future containment and epidemic control? * Understanding the effects of confinement and social distancing: what are the effects of confinement and social distancing on society and households? What are the mental health consequences? The social and domestic repercussions? * Early warning and preparedness: how do we re-enforce our health infrastructure and ecosystem (including medical devices and drug supply) to be better prepared and how do we protect our health workers and caregivers? * Preserving the environment and our health: connections between climate change, biodiversity loss and the origin of viral disease including socioeconomic dynamics leading to infectious disease outbreaks and sanitary crisis; Learnings from COVID-19 for mitigating future related crises in climate and biodiversity

The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Timely and reliable laboratory data are an essential component of a well-functioning national health system. This FOA will support strengthening the quality, accessibility, and sustainability of the NHLS across a six-tiered network, i.e., at the national, zonal, regional, district, health center, and dispensary levels. Technical assistance will focus on improving the quality assurance of HIV rapid testing, TB microscopy and GeneXpert; Early Infant Diagnosis (EID) and Viral Load (VL) testing; establishment and maintenance of efficient sample referral system and transport networks; implementation of laboratory Quality Management Systems; implementation of Laboratory Information Management Systems; scale up of EID and VL monitoring programs; quantification and forecasting of laboratory commodities; HIV Drug Resistance Surveillance; and, effective use of laboratory data for program management.

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Also Listed under R21

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDA's exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTP's) mission by utilizing the World Health Organization's (WHO) Member States' expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.

The purpose of this funding opportunity announcement (FOA) is to support research to develop and qualify a Patient Reported Outcome (PRO) for Non-Cystic Fibrosis Bronchiectasis (NCFB) under FDA's Drug Development Tools Qualification Program. This would include the qualitative phase of developing the instrument, quantitative phase of testing the instrument, and qualification of the instrument. It is expected that this qualified PRO would help improve upon the current design, conduct, and interpretation of anti-infective clinical trials in NCFB patients, for which optimal endpoints are currently lacking. This work directly aligns with FDA's research area of interest to "stimulate innovation in clinical evaluations and personalized medicine to improve product performance and patient outcomes.  

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice.

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

This Funding Opportunity Announcement (FOA) invites applications for infrastructure support to advance the development of efficacy and/or effectiveness research on recovery support services for those who were or who are being maintained on medications for the treatment of opioid use disorder. The infrastructure support will facilitate multi-stakeholder (e.g. researchers and students, payors, providers, individuals in recovery) research networks through meetings, conferences, small-scale pilots, data development work, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and to build resources for advancing recovery support services research. Network applications are to support research related to the following priority recovery support services (1) peer-based recovery support, (2) recovery community centers, (3) active recovery communities, (4) recovery residences, (5) education-based recovery support services, and (6) continuing care models, or others proposed by applicants.

We are pleased to announce three new Generation Rx requests for proposals, targeting four of the states that have been especially hard hit by the opioid epidemic: Ohio, Kentucky, Tennessee, and West Virginia. Please find brief details, downloadable RFPs, budget template and FAQs below. We invite you to review each of these grant opportunities, and apply for one or more to address the needs in your community. Prevention Education for Youth Best Practices in Pain Medication Use and Patient Engagement: Community-Level Response to the Opioid Crisis: The Cardinal Health Foundation has engaged content specialists to provide technical assistance to grantees and to create learning communities. We also anticipate convening grantees within the next 12 months for further learning.

This initiative will support exploratory projects that exploit HIV or host genomic or nucleomic information to understand HIV latency in individuals with substance use disorders (SUDs).

The Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Substance Abuse Treatment and Prevention are accepting applications for the fiscal year (FY) 2018 Opioid State Targeted Response (STR) Technical Assistance (TA) grant. This grant will be provided to a single entity who will serve as the central coordinating point for ensuring the requirements of this funding opportunity are met. Although there is a single grantee, applications including a consortia with other national allied professional associations are encouraged. The purpose of this program is to identify local physicians, other clinicians, and other providers, for example, advance practice nurses, physician assistants, peers and other healthcare professionals with expertise in treatment and in recovery services for opioid use disorders (OUDs). Based on a state, territory, or tribal nation's assessed need, these providers will serve as the primary providers of federally supported TA for the program's successful implementation. The goal of this TA is to ensure the provision of evidence-based prevention, treatment, and recovery support programs/services across the Opioid STR program.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations.

Undertake research activities that would entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic; and Support and promote the partnership of law enforcement and public health agencies, whose collaboration is critical to reducing overdose and other harms of opioid (mis)use. This ongoing opioid overdose epidemic presents new challenges to public health and public safety officials, medical professionals, local communities, and other stakeholders invested in curbing rates of accidental death. Preparing regional and community leaders to respond effectively to the public health emergency that is today's opioid overdose crisis (and be prepared to take on that crisis as it evolves tomorrow) is essential for achieving the shared goal of preventing fatal overdose and saving lives. ONDCP expects to award one Federal grant under the Combating Opioid Overdose through Community-Level Intervention Initiative for a 1-year period, beginning approximately September 2017. The successful non-Federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal opioid-related overdoses and will work to coordinate the often decentralized state and local efforts to assess and respond to opioid-related overdoses.

One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This RFA supports formative research to support development of stigma reduction interventions, as well as pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.